clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Gram-Negative Bacterial Infections D016905 16 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
IgA Deficiency D017098 2 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Tooth, Nonvital D019553 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Renal Insufficiency D051437 8 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Sacroiliitis D058566 1 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Yakoob J et al. Prevalence of non Helicobacter pylori species in patients presenting with dyspepsia. 2012 BMC Gastroenterol pmid:22226326
Reva I et al. Virulence genotypes and drug resistance of Helicobacter pylori from Vladivostok, Russia: another feature in the Far East. 2012 Microbiol. Immunol. pmid:22211953
Park SJ et al. Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection. 2012 Allergy Asthma Immunol Res pmid:22211173
Ohtani M et al. Amino acid and vitamin supplementation improved health conditions in elderly participants. 2012 J Clin Biochem Nutr pmid:22448099
[Experience with treatment of chronic polypoid rhinosinusitis using low doses of clarithromycin in the postoperative period]. 2012 Vestn. Otorinolaringol. pmid:22678641
Lotfy HM and Abdel-Monem Hagazy M Comparative study of novel spectrophotometric methods manipulating ratio spectra: an application on pharmaceutical ternary mixture of omeprazole, tinidazole and clarithromycin. 2012 Spectrochim Acta A Mol Biomol Spectrosc pmid:22683662
Rajper S et al. Macrolide and fluoroquinolone resistance in Helicobacter pylori isolates: an experience at a tertiary care centre in Pakistan. 2012 J Pak Med Assoc pmid:23866399
Goswami S et al. Anti-Helicobacter pylori potential of artemisinin and its derivatives. 2012 Antimicrob. Agents Chemother. pmid:22687518
Cuadrado-Lavín A et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. 2012 J. Antimicrob. Chemother. pmid:22687889
Perez AP et al. Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. 2012 Int J Nanomedicine pmid:22457595
González-Martínez R et al. Antibiotic prescription in the treatment of odontogenic infection by health professionals: a factor to consensus. 2012 Med Oral Patol Oral Cir Bucal pmid:22143715
Gisbert JP and Calvet X Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. 2012 Aliment. Pharmacol. Ther. pmid:22129228
Breda R et al. [Mycobacterium massiliense bone infection]. 2012 Med Mal Infect pmid:22154522
Takahashi E et al. Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. 2012 J. Virol. pmid:22896605
Greenstein RJ et al. Vitamins A & D inhibit the growth of mycobacteria in radiometric culture. 2012 PLoS ONE pmid:22235314
Chung JW et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. 2012 J. Gastroenterol. Hepatol. pmid:22849546
Chan A et al. A case of wrist tenosynovitis caused by Mycobacterium kansasii in a renal transplant recipient. 2012 Transpl Infect Dis pmid:22822725
Kanazu T et al. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats. 2012 Biopharm Drug Dispos pmid:22447511
Gao M et al. The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD, and Zn levels in pretreatment and posttreatment. 2012 Urology pmid:22100490
Zullo A et al. Role of gastritis pattern on Helicobacter pylori eradication. 2012 Intern Emerg Med pmid:22105372
von Müller L et al. [Current data and trends on the development of antibiotic resistance of Clostridium difficile]. 2012 Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz pmid:23114440
Davies BS et al. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. 2012 Scand. J. Infect. Dis. pmid:23078529
Madi D et al. Successful treatment of cerebral toxoplasmosis with clindamycin: a case report. 2012 Oman Med J pmid:23074553
Qian J et al. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. 2012 Helicobacter pmid:23067317
Liang J et al. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial. 2012 Helicobacter pmid:23066868
Erol E et al. Antibiotic susceptibility patterns of Crossiella equi and Amycolatopsis species causing nocardioform placentitis in horses. 2012 J. Vet. Diagn. Invest. pmid:23051830
Espinal DA et al. [Human metapneumovirus in children: first cases in Colombia]. 2012 Biomedica pmid:23242289
Saracino IM et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. 2012 J Gastrointestin Liver Dis pmid:23256118
Tsay FW et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. 2012 J. Gastroenterol. Hepatol. pmid:21871025
Boyanova L et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. 2012 J. Med. Microbiol. pmid:21873378
Saito R et al. Molecular mechanism of macrolide-lincosamide resistance in Moraxella catarrhalis. 2012 J. Med. Microbiol. pmid:22820696
Flamm RK et al. Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. 2012 Diagn. Microbiol. Infect. Dis. pmid:22819241
Kuo CH et al. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. 2012 Gastroenterol Res Pract pmid:22792095
Marzouk H et al. The utility of nasopharyngeal culture in the management of chronic adenoiditis. 2012 Int. J. Pediatr. Otorhinolaryngol. pmid:22784508
Hu FL et al. [Jinghuaweikang capsules combined with triple therapy in the treatment of Helicobacter pylori associated gastritis and duodenal ulcer and analysis of antibiotic resistance: a multicenter, randomized, controlled, clinical study]. 2012 Zhonghua Yi Xue Za Zhi pmid:22781295
Kotsaki A and Giamarellos-Bourboulis EJ Emerging drugs for the treatment of sepsis. 2012 Expert Opin Emerg Drugs pmid:22780561
Fiorini G et al. Newer agents for Helicobacter pylori eradication. 2012 Clin Exp Gastroenterol pmid:22767998
Sakinc T et al. Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin. 2012 BMC Res Notes pmid:23110798
Robinson P et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. 2012 Pediatr. Pulmonol. pmid:22266895
Blumenthal A et al. M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection. 2012 PLoS ONE pmid:22649518
Korownyk C and Kolber MR Is quadruple therapy the new triple therapy for H pylori? 2012 Can Fam Physician pmid:22267623
Huang J et al. [A 10-day sequential therapy for eradication of Helicobacter pylori infection in children]. 2012 Zhonghua Er Ke Za Zhi pmid:23158730
Sugimoto M and Furuta T Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. 2012 Clin Exp Gastroenterol pmid:22649281
Mumoli N and Cei M Clinical images: community-acquired pneumonia. 2012 CMAJ pmid:22271912
Henneman A and Thornby KA Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics. 2012 Am J Health Syst Pharm pmid:22644980
English ML et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. 2012 Antimicrob. Agents Chemother. pmid:22290969
Tatar EÇ et al. Prevalence of biofilms and their response to medical treatment in chronic rhinosinusitis without polyps. 2012 Otolaryngol Head Neck Surg pmid:22241786
Birteksöz-Tan AS and Zeybek Z Postantibiotic effect of various antibiotics on Legionella pneumophila strains isolated from water systems. 2012 Folia Microbiol. (Praha) pmid:22627604
Chang WJ et al. Successful salvage treatment of steroid-refractory bronchiolar COP with low-dose macrolides. 2012 Pathol. Int. pmid:22243785
Burt HJ et al. Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4. 2012 Drug Metab. Dispos. pmid:22621802
Lismond A et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. 2012 Int. J. Antimicrob. Agents pmid:22245497
Chhabra N et al. Pharmacotherapy for multidrug resistant tuberculosis. 2012 J Pharmacol Pharmacother pmid:22629081
Prasad R Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies. 2012 Lung India pmid:22628931
Goodman JJ and Martin SI Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. 2012 Ther Clin Risk Manag pmid:22547933
Werth S et al. Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. 2012 Ther Clin Risk Manag pmid:22547932
Sereni G et al. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22969227
Bajaj P et al. Locally delivered 0.5% clarithromycin, as an adjunct to nonsurgical treatment in chronic periodontitis with well-controlled type 2 diabetes: a randomized controlled clinical trial. 2012 J Investig Clin Dent pmid:22976782
Akelma AZ et al. Clarithromycin in treatment of acute asthma exacerbations: principles of appropriate antibiotic use. 2012 Pediatr Allergy Immunol pmid:22984834
Karlgren M et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. 2012 J. Med. Chem. pmid:22541068
Monno R et al. Helicobacter pylori clarithromycin resistance detected by Etest and TaqMan real-time polymerase chain reaction: a comparative study. 2012 APMIS pmid:22882260
Pandya GJ et al. Unilateral lobar pulmonary edema. 2012 J Assoc Physicians India pmid:23547417
Fakheri H et al. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. 2012 Helicobacter pmid:22221615
Georgopoulos S et al. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. 2012 Helicobacter pmid:22221616
Adrjanowicz K et al. Molecular dynamics in supercooled liquid and glassy states of antibiotics: azithromycin, clarithromycin and roxithromycin studied by dielectric spectroscopy. Advantages given by the amorphous state. 2012 Mol. Pharm. pmid:22540343
Gisbert JP and Calvet X Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. 2012 Clin Exp Gastroenterol pmid:22457599
Hahn DL et al. Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity. 2012 PLoS ONE pmid:22545149
Wang H et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. 2012 Zhonghua Jie He He Hu Xi Za Zhi pmid:22455967
Zautner AE Adenotonsillar disease. 2012 Recent Pat Inflamm Allergy Drug Discov pmid:22452646
Cronnolly B and Pegrum H Fentanyl-clarithromycin interaction. 2012 BMJ Case Rep pmid:22778456
Berti AD et al. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. 2012 Antimicrob. Agents Chemother. pmid:22802248
Iino R et al. A microfluidic device for simple and rapid evaluation of multidrug efflux pump inhibitors. 2012 Front Microbiol pmid:22347225
Khavinson VKh et al. Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins. 2012 Bull. Exp. Biol. Med. pmid:22803148
Dholakia Y et al. Drug-resistant tuberculosis: Study of clinical practices of chest physicians, Maharashtra, India. 2012 Lung India pmid:22345911
Lachter J et al. Yellow brain culinary-medicinal mushroom, Tremella mesenterica Ritz.:Fr. (higher Basidiomycetes), is subjectively but not objectively effective for eradication of Helicobacter pylori: a prospective controlled trial. 2012 Int J Med Mushrooms pmid:22339708
Molina-Infante J et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. 2012 Helicobacter pmid:22759326
Kongchayanun C et al. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. 2012 Helicobacter pmid:22759328
Song JY et al. Case series of mycobacterium abscessus infections associated with a trigger point injection and epidural block at a rural clinic. 2012 Epidemiol Health pmid:22323979
Hirata Y et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. 2012 Int. J. Antimicrob. Agents pmid:22321702
Lopes R et al. [Antibiomania: a case of a manic episode induced by clarithromycin]. 2011 Sep-Oct Acta Med Port pmid:22525636
Yasar KK et al. Successfully treated Mycobacterium abscessus mastitis: a rare cause of breast masses. 2011 Oct-Dec Indian J Med Microbiol pmid:22120809
Eisig JN et al. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. 2011 Oct-Dec Arq Gastroenterol pmid:22147131
Abadi AT et al. High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran. 2011 Nov-Dec Saudi J Gastroenterol pmid:22064338
Bilgili SG et al. Phototoxic dermatitis due to Chenopodium album in a child. 2011 Nov-Dec Pediatr Dermatol pmid:21854411
Lee CY et al. Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature. 2011 Nov-Dec Can J Cardiol pmid:21907534
Zeng M et al. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. 2011 Nov-Dec Am J Rhinol Allergy pmid:22185725
Mello CF and Negra MD Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital. 2011 May-Jun Braz J Infect Dis pmid:21670928
Schmidt D [The choice of treatment in HP associated ulcer: metronidazole or amoxicillin--nothing else!]. 2011 May 4-10 Lakartidningen pmid:21809531
Steyaert S et al. Soft tissue infections with atypical mycobacteria in two patients with inflammatory rheumatic diseases using TNF-inhibitors and/or leflunomide. 2011 Mar-Apr Acta Clin Belg pmid:21630616
Söderberg KC and Böttiger Y [Difficult choice between clarithromycin and metronidazole in polyneuropathy]. 2011 Mar 9-15 Lakartidningen pmid:21744557
Chung JW et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. 2011 Jan-Feb Hepatogastroenterology pmid:21510323
Galmés-Truyols A et al. An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. 2011 Aug-Sep Enferm. Infecc. Microbiol. Clin. pmid:21684045
Umezawa M et al. Clarithromycin and telithromycin increases interleukin-10 expression in the rat endometriosis model. 2011 Cytokine pmid:21665488
Mazzoleni LE et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. 2011 Arch. Intern. Med. pmid:22123802
Agrawal A et al. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. 2011 Indian J Gastroenterol pmid:21416318
Liu G et al. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. 2011 Helicobacter pmid:21923681
Salik D and Del Marmol V Refractory Hand Ulceration: A Case of Chronic Ulceration and Sporotrichoid Spread in a Fish Tank Hobbyist following Mycobacterium marinum Infection. 2011 Case Rep Dermatol pmid:21792350
Molina-Infante J and Gisbert JP Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. 2011 Gut pmid:21193443
Kim SY and Jung SW [Helicobacter pylori eradication therapy in Korea]. 2011 Korean J Gastroenterol pmid:21873820
Talpaert MJ et al. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. 2011 J. Antimicrob. Chemother. pmid:21676904
Boisson-Dupuis S et al. IL-12Rβ1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. 2011 PLoS ONE pmid:21533230